Category: Ecosystem News

SD-101 is a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. TriSalus plans to further develop SD-101 as an oncology therapeutic. F...

New Iridium, a company developing commercialized  photocatalysis technologies to accelerate drug development and manufacturing, has been awarded a National Science Foundation (NSF) Small Business Tech...

KromaTiD, Inc. announced today the launch of its new product dGH In-Site™, a single-cell, high resolution, genome-wide DNA insert tracking assay. dGH In-Site™ enables researchers to directly measure t...

Just a few weeks ago, the company filed for an IPO. Now, it's being acquired. Find out more in the article from Denver Business Journal.

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitati...

Edgewise Therapeutics, a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of Kirsten L. Gruis, M.D., M.S. to the newly create...

ArcherDX, Inc. today announced it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer Monitoring (PCM™) assays to understand the potential benefits of minim...

Cetya Therapeutics, Inc. today announced issuance of US Patent No. 10,676,504 and Australian Patent No. 2016229324 covering CT-102, Cetya’s proprietary HDAC inhibitor. CT-102 has demonstrated excellen...

Flagship Biosciences, providers of expert tissue data insights, today announced that Aymii Couzelis has been named to its executive team as Chief Information Officer. Aymii brings over 20 years of exp...

ARCA biopharma, Inc. (Nasdaq: ABIO) today announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor of tissue factor (TF), as a potential treatment for COVID-19 ass...